- Home
- FWRG vs SANA Comparison
FWRG vs SANA Comparison
Compare FWRG & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- SANA
- Stock Information
- Founded
- FWRG 1983
- SANA 2018
- Country
- FWRG United States
- SANA United States
- Employees
- FWRG N/A
- SANA N/A
- Industry
- FWRG Restaurants
- SANA Medicinal Chemicals and Botanical Products
- Sector
- FWRG Consumer Discretionary
- SANA Health Care
- Exchange
- FWRG Nasdaq
- SANA Nasdaq
- Market Cap
- FWRG 1.1B
- SANA 983.4M
- IPO Year
- FWRG 2021
- SANA 2021
- Fundamental
- Price
- FWRG $17.96
- SANA $3.47
- Analyst Decision
- FWRG Strong Buy
- SANA Strong Buy
- Analyst Count
- FWRG 8
- SANA 7
- Target Price
- FWRG $21.88
- SANA $7.83
- AVG Volume (30 Days)
- FWRG 1.4M
- SANA 3.9M
- Earning Date
- FWRG 11-04-2025
- SANA 11-06-2025
- Dividend Yield
- FWRG N/A
- SANA N/A
- EPS Growth
- FWRG N/A
- SANA N/A
- EPS
- FWRG 0.08
- SANA N/A
- Revenue
- FWRG $1,169,440,000.00
- SANA N/A
- Revenue This Year
- FWRG $22.25
- SANA N/A
- Revenue Next Year
- FWRG $16.18
- SANA N/A
- P/E Ratio
- FWRG $224.10
- SANA N/A
- Revenue Growth
- FWRG 17.27
- SANA N/A
- 52 Week Low
- FWRG $12.90
- SANA $1.26
- 52 Week High
- FWRG $22.71
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- FWRG 57.42
- SANA 38.80
- Support Level
- FWRG $15.21
- SANA $3.16
- Resistance Level
- FWRG $17.86
- SANA $4.10
- Average True Range (ATR)
- FWRG 0.93
- SANA 0.35
- MACD
- FWRG 0.02
- SANA -0.08
- Stochastic Oscillator
- FWRG 76.79
- SANA 26.42
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.